2025
Ensemble Deep Learning Algorithm for Structural Heart Disease Screening Using Electrocardiographic Images PRESENT SHD
Dhingra L, Aminorroaya A, Sangha V, Pedroso A, Shankar S, Coppi A, Foppa M, Brant L, Barreto S, Ribeiro A, Krumholz H, Oikonomou E, Khera R. Ensemble Deep Learning Algorithm for Structural Heart Disease Screening Using Electrocardiographic Images PRESENT SHD. Journal Of The American College Of Cardiology 2025, 85: 1302-1313. PMID: 40139886, DOI: 10.1016/j.jacc.2025.01.030.Peer-Reviewed Original ResearchConceptsStructural heart diseaseYale-New Haven HospitalTransthoracic echocardiogramRisk stratificationHeart failureLeft-sided valvular diseaseSevere left ventricular hypertrophyLeft ventricular ejection fractionReceiver-operating characteristic curveVentricular ejection fractionLeft ventricular hypertrophyHeart disease screeningELSA-BrasilEnsemble deep learning algorithmRisk of deathConvolutional neural network modelEjection fractionEnsemble deep learning approachVentricular hypertrophyDeep learning algorithmsNew Haven HospitalDeep learning approachValvular diseaseNeural network modelClinical cohortCharting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions
Cheng R, Villela M, Masoumi A, Esposito M, Baran D, Rommel K, Fudim M, Mahfoud F, Lansky A, Burkhoff D, Kapur N. Charting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102569. DOI: 10.1016/j.jscai.2025.102569.Peer-Reviewed Original ResearchTranscatheter valve therapiesHeart failureValve therapyCardiogenic shockCoronary interventionLow ejection fractionDevice-based therapiesTraining pathwaysComplexity of therapeutic optionsEndomyocardial biopsyEjection fractionImplantable pressure sensorTherapeutic optionsHeart transplantationAdvanced HFAtrial pressureImprove outcomesCardiology trainingA series of hydroxychloroquine-associated cardiotoxicity presenting with heart failure
Nazarenko N, Maliha M, Parker M, Borkowski P, Csecs I, Tauras J, Julia Shin J, Pullman J, Sims D, Rochlani Y. A series of hydroxychloroquine-associated cardiotoxicity presenting with heart failure. Annals Of Medicine And Surgery 2025, 87: 1334-1340. DOI: 10.1097/ms9.0000000000002997.Peer-Reviewed Original ResearchSystemic lupus erythematosusHCQ useHeart failureCardiac abnormalitiesCardiac magnetic resonance imagingDose-dependent complicationsRheumatoid arthritisCases of SLE patientsDiscontinuation of hydroxychloroquineResolution of symptomsLong-term therapyEarly detectionShortness of breathA-V blockHCQ therapyMagnetic resonance imagingPrompt discontinuationEndomyocardial biopsyPulmonary hypertensionEjection fractionHF therapyCardiac symptomsImprove patient outcomesSLE patientsSjogren's syndromeNovel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve densityIn-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial.
Nouhravesh N, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, Sarwat S, Sharma K, Williamson K, Starling R, Lepage S, Zieroth S, Solomon S, Mentz R. In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial. Journal Of The American Heart Association 2025, 14: e037899. PMID: 39968788, DOI: 10.1161/jaha.124.037899.Peer-Reviewed Original ResearchOut-of-hospitalWorsening renal functionSafety end pointNT-proBNP changesEjection fractionIn-hospitalNT-proBNPHeart failureRenal functionSymptomatic hypotensionTime-averaged proportional changeEnd pointsWorsening heart failure eventEffects of Sac/ValSacubitril/valsartan (sac/valWorsening HF eventsHeart failure eventsStatistically significant differenceWorsening HFDouble-blindHF hospitalizationSac/ValCardiovascular deathWeek 4HF eventsAssociation between three-dimensional right ventricular ejection fraction and in-hospital outcomes in patients undergoing cardiac surgery. A multicenter study
Posada-Martinez E, Ivey-Miranda J, Ortiz-Leon X, Arias-Godinez J, Fritche-Salazar J, Rodriguez-Zanella H, Ruiz Esparza-Dueñas M, Romero-Zertuche D, Silvestre-Flores I, Morales-Portano J, Orea-Tejeda A, Rojas-Serrano J, McNamara R, Reyes Lopez P, Sugeng L. Association between three-dimensional right ventricular ejection fraction and in-hospital outcomes in patients undergoing cardiac surgery. A multicenter study. Journal Of The American Society Of Echocardiography 2025 PMID: 39984139, DOI: 10.1016/j.echo.2025.02.008.Peer-Reviewed Original ResearchRight ventricular ejection fractionRV function parametersVentricular ejection fractionCardiac surgeryEuroSCORE IIPrimary outcomeEjection fractionMechanical ventilationMulticenter study of adult patientsRight ventricular (RV) functionParameters of RV systolic functionPredictors of in-hospital mortalityStudy of adult patientsFunction parametersRV systolic functionProspective multicenter studyAssociated with shorter timeAccurate risk stratificationEvaluation of patientsIn-hospital mortalityIn-hospital outcomesTemporary ventricular assist devicesTransesophageal echocardiogramExploratory endpointsPrimary endpointEffect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Shah T, Zhang Z, Shah H, Fanaroff A, Nathan A, Parise H, Lutz J, Sugeng L, Bellumkonda L, Redfors B, Omerovic E, Petrie M, Vora A, Fiorilli P, Kobayashi T, Ahmad Y, Forrest J, Giri J, Herrmann H, Lansky A. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovascular Interventions 2025, 18: 738-748. PMID: 39985508, DOI: 10.1016/j.jcin.2024.11.036.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsCotransporter-2 inhibitorsAortic stenosisEffects of sodium-glucose cotransporter-2 inhibitorsProgression of aortic stenosisBaseline AS severityAssociated with slower progressionEchocardiographic follow-upRetrospective electronic medical record dataAortic valve sclerosisDisease-related morbidityChronic kidney diseaseSGLT2i usageRates of diabetesSevere ASAS severityEjection fractionFollow-upPrimary outcomeGt;1 yearKidney diseaseMedical record dataYale New Haven Health SystemPatientsObservational studyNatriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex
Gandhi P, Runels T, Han L, Skanderson M, Bastian L, Brandt C, Hauser R, Feder S, Rodwin B, Farmer M, Bean-Mayberry B, Placide S, Gaffey A, Akgün K. Natriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex. Heart & Lung 2025, 71: 25-31. PMID: 39970822, DOI: 10.1016/j.hrtlng.2025.02.001.Peer-Reviewed Original ResearchConceptsNatriuretic peptide testingHeart failure hospitalizationFacility characteristicsVeterans Affairs Healthcare SystemPeptide testingSex-based differencesFacility-related factorsSex-stratified modelsAssociated with increased likelihoodAssociated with decreased likelihoodHealthcare systemHF diagnosisEjection fractionCardiac comorbiditiesFailure hospitalizationClinical outcomesLogistic regressionAtrial fibrillationHeart failureVeteransClinical covariatesPatientsAdmissionSexAssociationThree-dimensional right ventricular ejection fraction: a strong predictor of outcomes in patients undergoing cardiac surgery, a multicenter study.
Posada-Martinez E, Ivey-Miranda J, Ortiz-Leon X, Arias-Godinez J, Fritche-Salazar J, Rodriguez-Zanella H, Esparza M, Romero-Zertuche D, Silvestre-Flores I, Morales-Portano J, Mcnamara R, Sugeng L. Three-dimensional right ventricular ejection fraction: a strong predictor of outcomes in patients undergoing cardiac surgery, a multicenter study. European Heart Journal - Cardiovascular Imaging 2025, 26: jeae333.356. DOI: 10.1093/ehjci/jeae333.356.Peer-Reviewed Original ResearchLower RV ejection fractionRV ejection fractionCardiac surgeryPredictors of outcomePrimary outcomeEjection fractionMulticenter studyMechanical ventilationRight ventricular (RV) functionCohort study of adult patientsLeft ventricular ejection fractionRV-pulmonary arterial couplingComposite of in-hospital mortalityMultivariate Cox regression modelStudy of adult patientsBackground Cardiac surgeryAortic valve repairRV function parametersVentricular ejection fractionAssociated with shorter timeEvaluation of patientsAssociated with in-hospital outcomesBaseline demographic characteristicsTomTec Imaging SystemsIn-hospital mortalityInterleukin-10 exhibit dose-dependent effects on macrophage phenotypes and cardiac remodeling after myocardial infarction
Zhang J, Rizk R, Li X, Lee B, Matthies M, Bietz K, Kim K, Huard J, Wang Y, Chen W. Interleukin-10 exhibit dose-dependent effects on macrophage phenotypes and cardiac remodeling after myocardial infarction. Frontiers In Physiology 2025, 15: 1481460. PMID: 39882328, PMCID: PMC11774956, DOI: 10.3389/fphys.2024.1481460.Peer-Reviewed Original ResearchIL-10 treatmentIL-10Dose-dependent effectMyocardial infarctionPost-MICardiac remodelingInterleukin-10Lower LV ejection fractionDoses of IL-10LV ejection fractionIL-10 administrationMyocardial gene expressionExogenous IL-10IL-10 secretionEffective dose rangePhenotypic transitionDose-dependent mannerLV fibrosisEjection fractionMouse MI modelCardiac functionCell infiltrationImmunomodulatory cytokinesContractile functionDose-dependentlySacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF
Nouhravesh N, Gunn A, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, Sarwat S, Sharma K, Williamson K, Starling R, Lepage S, Zieroth S, Solomon S, Mentz R. Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF. European Journal Of Heart Failure 2025 PMID: 39792134, DOI: 10.1002/ejhf.3579.Peer-Reviewed Original ResearchAngiotensin receptor blockersAngiotensin-converting enzyme inhibitorsNT-proBNPHeart failureEjection fractionProspective Comparison of ARNITime-averaged proportional changeN-terminal pro-B-type natriuretic peptideWeek 4Pro-B-type natriuretic peptideBaseline to week 4Renin-angiotensin system inhibitorsSacubitril/valsartan (sac/valWorsening renal functionTime of randomizationRandomized controlled trialsWorsening HFDouble-blindPrimary endpointRenal functionNatriuretic peptideSymptomatic hypotensionDecompensated HFpEFReceptor blockersSafety endpointsBeyond convention: non-compacted myocardium, ventricular tachycardia, and systolic dysfunction in dextrocardia patients: a case series
Nazarenko N, Maliha M, Cerna L, Abittan N, Borkowski P, Csecs I, Garcia M. Beyond convention: non-compacted myocardium, ventricular tachycardia, and systolic dysfunction in dextrocardia patients: a case series. Annals Of Medicine And Surgery 2025, 87: 56-61. PMID: 40109641, PMCID: PMC11918691, DOI: 10.1097/ms9.0000000000002855.Peer-Reviewed Original ResearchLeft ventricleDextrocardia patientsICD placementSeverely reduced ejection fractionHigh risk of sudden cardiac deathRight-sided pleural effusionRisk of sudden cardiac deathAbnormal myocardial developmentYears of follow-upNon-compacted myocardiumTreated with amiodaroneSubsegmental pulmonary embolismTreated with enoxaparinLong-term outcomesSudden cardiac deathSystolic dysfunctionEvent-freeWorsening dyspneaEjection fractionPulmonary embolismAtrial dilatationPleural effusionConduction abnormalitiesMedical therapyCase seriesWin Ratio Sensitivity Analysis Using A Modified Hierarchical Composite Outcome: Insights From The Paraglide-hf
Shoji S, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, Williamson K, Sarwat S, Starling R, Desai A, Zieroth S, Solomon S, Braunwald E, Mentz R. Win Ratio Sensitivity Analysis Using A Modified Hierarchical Composite Outcome: Insights From The Paraglide-hf. Journal Of Cardiac Failure 2025, 31: 181. DOI: 10.1016/j.cardfail.2024.10.011.Peer-Reviewed Original ResearchNT-proBNPEjection fractionComposite outcomeRenal outcomesHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideSacubitril/valsartan (sac/valWorsening HF eventsNT-proBNP changesClinically significant eventsNatriuretic peptideRandomized patientsAssessment of treatment effectsHF hospitalizationSac/ValHF patientsCardiovascular deathTreatment effectsHF eventsTreatment benefitComprehensive assessment of treatment effectsPatientsPrimary analysisHF visitsEffects Of Angiotensin-Neprilysin Inhibition In Women Versus Men With Mildly Reduced Or Preserved Ejection Fraction And Worsening Heart Failure: Insights From PARAGLIDE-HF
Rambarat P, Erickson T, Cyr D, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Zieroth S, Williamson K, Solomon S, Braunwald E, Mentz R. Effects Of Angiotensin-Neprilysin Inhibition In Women Versus Men With Mildly Reduced Or Preserved Ejection Fraction And Worsening Heart Failure: Insights From PARAGLIDE-HF. Journal Of Cardiac Failure 2025, 31: 330-331. DOI: 10.1016/j.cardfail.2024.10.383.Peer-Reviewed Original ResearchNT-proBNPHeart failureAmino-terminal pro-B type natriuretic peptideTime-averaged proportional changePro B-type natriuretic peptideTime-averaged reductionIncidence of adverse eventsWorsening heart failureAngiotensin-neprilysin inhibitionCoronary artery diseaseHigh-risk populationDifferential treatment effectsDrug dosage levelsTreatment effectsHFpEF therapyEjection fractionPrimary endpointNatriuretic peptideNo significant differenceRenal functionAdverse eventsSac/ValSubgroup analysisArtery diseaseWeek 4
2024
The association of reduced ejection fraction with the outcomes of endovascular abdominal aortic aneurysm repair
Bellamkonda K, Zogg C, Desai N, Strosberg D, Stone D, Guzman R, Ochoa Chaar C. The association of reduced ejection fraction with the outcomes of endovascular abdominal aortic aneurysm repair. Journal Of Vascular Surgery 2024, 81: 866-876. PMID: 39725244, DOI: 10.1016/j.jvs.2024.12.039.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Aneurysm, AbdominalBlood Vessel Prosthesis ImplantationCardiomyopathiesDatabases, FactualEndovascular ProceduresFemaleHumansMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesRisk AssessmentRisk FactorsStroke VolumeTime FactorsTreatment OutcomeUnited StatesVentricular Function, LeftConceptsEndovascular aneurysm repairEjection fractionReduced EFIschemic cardiomyopathyNormal EFNonischemic cardiomyopathyAneurysm repairOutcomes of endovascular abdominal aortic aneurysm repairOutcomes of endovascular aneurysm repairEndovascular abdominal aortic aneurysm repairAssociated with higher 30-day mortalitySymptomatic abdominal aortic aneurysmElective endovascular aneurysm repairAbdominal aortic aneurysm repairHigher 30-day mortalityVascular Quality Initiative databaseAssociated with high mortalityAortic aneurysm repairVascular Surgery guidelinesAbdominal aortic aneurysmLong-term mortalityVascular Quality InitiativeSeverity of cardiomyopathyReduction of EFSurgery guidelinesSGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts
Goedeke L, Ma Y, Gaspar R, Nasiri A, Lee J, Zhang D, Galsgaard K, Hu X, Zhang J, Guerrera N, Li X, LaMoia T, Hubbard B, Haedersdal S, Wu X, Stack J, Dufour S, Butrico G, Kahn M, Perry R, Cline G, Young L, Shulman G. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. Journal Of Clinical Investigation 2024, 134: e176708. PMID: 39680452, PMCID: PMC11645152, DOI: 10.1172/jci176708.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter type 2Heart failureKetone oxidationGas chromatography-mass spectrometryFatty acid oxidationLeft ventricular ejection fractionReduced myocardial oxidative stressVentricular ejection fractionKetone supplementationWeeks of treatmentMyocardial oxidative stressDecreased pyruvate oxidationInduce heart failurePlasma glucose levelsIn vivo effectsSGLT2i treatmentEjection fractionAssociated with improvementsAwake ratsSGLT2 inhibitionCardioprotective benefitsLiquid chromatography-tandem mass spectrometryPlasma ketonesRates of ketonizationChromatography-tandem mass spectrometryThe Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study
Chan N, Einstein A, Teruya S, Rodriguez C, Helmke S, Cuomo M, Santana D, Castillo M, Smiley D, Sabogal N, Lamour S, Winburn M, Fine D, de Freitas C, Kattan C, Miller E, Maurer M, Ruberg F. The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study. The American Journal Of Cardiology 2024, 237: 60-64. PMID: 39581521, PMCID: PMC11761373, DOI: 10.1016/j.amjcard.2024.11.019.Peer-Reviewed Original ResearchATTR-CATransthyretin cardiac amyloidosisProportion of womenCardiac amyloidosisReferral cohortLower left ventricular mass indexHigher left ventricular ejection fractionPrevalence of ATTR-CAATTR-CA patientsWild-type diseaseVentricular ejection fractionVentricular mass indexPosterior wall thicknessAscertainment cohortLeft ventricular hypertrophyReduce sex disparitiesHigher proportion of womenATTRwt-CAEjection fractionEchocardiographic evidenceHeart failureMass indexSex-specific differencesSevere phenotypeSex distributionThe Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study
Mark J, Colombo R, Alfonso C, Llanos A, Collado E, Larned J, Giese G, Dyal M, Nanna M, Damluji A. The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study. JACC Advances 2024, 3: 101358. PMID: 39600986, PMCID: PMC11588852, DOI: 10.1016/j.jacadv.2024.101358.Peer-Reviewed Original ResearchAdverse cardiovascular eventsCatheter ablationAtrial fibrillationCardiovascular eventsHeart failureFrail patientsHospital lengthNonfrail patientsReducing major adverse cardiovascular eventsAssociated with worse outcomesMajor adverse cardiovascular eventsReduced ejection fractionHospital length of stayIn-hospital mortalityLonger hospital lengthAssociated with increased oddsDischarge dispositionInfluence of frailtyMultivariate regression analysisNationwide Inpatient SampleImpact of frailtyLength of stayPrevalence of frailtyEjection fractionJohns Hopkins Adjusted Clinical GroupsWin Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF
Shoji S, Cyr D, Hernandez A, Velazquez E, Ward J, Williamson K, Sarwat S, Starling R, Desai A, Zieroth S, Solomon S, Mentz R. Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF. American Heart Journal 2024, 280: 70-78. PMID: 39505123, DOI: 10.1016/j.ahj.2024.10.020.Peer-Reviewed Original ResearchNT-proBNPComposite outcomeRenal outcomesEjection fractionHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideNT-proBNP thresholdsNT-proBNP changesClinically significant eventsNatriuretic peptideAssessment of treatment effectsHF hospitalizationCardiovascular deathTreatment effectsTreatment benefitComprehensive assessment of treatment effectsPrimary analysisValsartanHF visitsSecondary analysisPatientsHierarchical outcomesOutcomesMortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Y K, Lee P, Chowdhury I, Schwartz R, Kang Y, Mangalesh S, Babapour G, Akman Z, Chang Y, Song J, Lessa Y, Damluji A, Nanna M, Nanna M. Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.1640. DOI: 10.1093/eurheartj/ehae666.1640.Peer-Reviewed Original ResearchRandomized controlled trialsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitReduced EFMeta-regressionEF patientsPreserved EFBB usersReperfusion eraMeta-analysisSubgroup analysisSystematic reviewPost-MIPost-MI careEffect of beta-blockersIncreased all-cause mortalityHistory of HFEvent-free periodAll-cause mortalityTemporal trendsStudy inclusion periodModern randomized controlled trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply